412 related articles for article (PubMed ID: 15710994)
41. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.
Tournoux-Facon C; Paoletti X; Barbare JC; Bouché O; Rougier P; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Bedenne L; Bonnetain F
J Hepatol; 2011 Jan; 54(1):108-14. PubMed ID: 21047696
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy.
Nanashima A; Omagari K; Sumida Y; Abo T; Fukuoha H; Takeshita H; Hidaka S; Tanaka K; Sawai T; Yasutake T; Nagayasu T; Mizuta Y; Ohba K; Ohnita K; Kadokawa Y
Hepatogastroenterology; 2009; 56(93):1137-40. PubMed ID: 19760957
[TBL] [Abstract][Full Text] [Related]
43. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score.
Kitai S; Kudo M; Minami Y; Ueshima K; Chung H; Hagiwara S; Inoue T; Ishikawa E; Takahashi S; Asakuma Y; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
Intervirology; 2008; 51 Suppl 1():86-94. PubMed ID: 18544953
[TBL] [Abstract][Full Text] [Related]
44. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy.
Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
J Gastroenterol Hepatol; 2012 Apr; 27(4):690-9. PubMed ID: 22436058
[TBL] [Abstract][Full Text] [Related]
45. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials.
Li X; Dong M; Lin Q; Chen ZH; Ma XK; Xing YF; Wan XB; Wen JY; Wei L; Chen J; Wu XY
Asia Pac J Clin Oncol; 2013 Mar; 9(1):86-92. PubMed ID: 23279888
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy.
Seong J; Shim SJ; Lee IJ; Han KH; Chon CY; Ahn SH
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1037-42. PubMed ID: 17234356
[TBL] [Abstract][Full Text] [Related]
47. A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution.
Toyama T; Hiramatsu N; Yakushijin T; Oze T; Nakanishi F; Yasumaru M; Mochizuki K; Kanto T; Takehara T; Kasahara A; Hayashi N
J Clin Gastroenterol; 2008 Mar; 42(3):317-22. PubMed ID: 18223490
[TBL] [Abstract][Full Text] [Related]
48. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
[TBL] [Abstract][Full Text] [Related]
49. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients.
Xu HX; Lu MD; Xie XY; Yin XY; Kuang M; Chen JW; Xu ZF; Liu GJ
Clin Radiol; 2005 Sep; 60(9):1018-25. PubMed ID: 16124984
[TBL] [Abstract][Full Text] [Related]
50. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.
Huo TI; Lin HC; Huang YH; Wu JC; Chiang JH; Lee PC; Lee SD
Cancer; 2006 Jul; 107(1):141-8. PubMed ID: 16708358
[TBL] [Abstract][Full Text] [Related]
51. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
[TBL] [Abstract][Full Text] [Related]
52. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy.
Nanashima A; Sumida Y; Morino S; Yamaguchi H; Tanaka K; Shibasaki S; Ide N; Sawai T; Yasutake T; Nakagoe T; Nagayasu T
Eur J Surg Oncol; 2004 Sep; 30(7):765-70. PubMed ID: 15296991
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
Am J Gastroenterol; 2005 Aug; 100(8):1764-71. PubMed ID: 16086713
[TBL] [Abstract][Full Text] [Related]
54. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy.
Chen TW; Chu CM; Yu JC; Chen CJ; Chan DC; Liu YC; Hsieh CB
Eur J Surg Oncol; 2007 May; 33(4):480-7. PubMed ID: 17129701
[TBL] [Abstract][Full Text] [Related]
55. Surgical indications for advanced hepatocellular carcinoma.
Shimada M; Yamashita Y; Hamatsu T; Rikimaru T; Hasegawa H; Gion T; Shirabe K; Takenaka K; Sugimachi K
Hepatogastroenterology; 2000; 47(34):1095-9. PubMed ID: 11020886
[TBL] [Abstract][Full Text] [Related]
56. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients.
Yen YH; Changchien CS; Wang JH; Kee KM; Hung CH; Hu TH; Lee CM; Lin CY; Wang CC; Chen TY; Huang YJ; Lu SN
Dig Liver Dis; 2009 Jun; 41(6):431-41. PubMed ID: 19185555
[TBL] [Abstract][Full Text] [Related]
57. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
58. Needle biopsy of hepatocellular carcinoma: assessment of prognostic contribution of histologic parameters including proliferating cell nuclear antigen labeling and correlations with clinical outcomes. Group d'Etude et de Traitement du Carcinoma Hépatocellulaire.
Chapel F; Guettier C; Chastang C; Rached AA; Mathieu D; Tepper M; Beaugrand M; Trinchet JC
Cancer; 1996 Mar; 77(5):864-71. PubMed ID: 8608476
[TBL] [Abstract][Full Text] [Related]
59. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization.
Dvorchik I; Carr BI
Cancer Detect Prev; 2007; 31(2):154-60. PubMed ID: 17416468
[TBL] [Abstract][Full Text] [Related]
60. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey.
Kitai S; Kudo M; Izumi N; Kaneko S; Ku Y; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Kadoya M; Matsuyama Y; Matsunaga T
Dig Dis; 2014; 32(6):717-24. PubMed ID: 25376289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
